Multiple Sclerosis

New science drives biopharma interest in neurological conditions

New science drives biopharma interest in neurological conditions

By

The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.

If Roche's Ocrevus is approved, the already competitive MS market will gain another player

If Roche's Ocrevus is approved, the already competitive MS market will gain another player

By

The experimental therapy is positioned to fill a market gap in primary progressive multiple sclerosis.

Five things for pharma marketers to know: Thursday, August 25, 2016

Five things for pharma marketers to know: Thursday, August 25, 2016

By

Mylan offers additional copay assistance for EpiPen amid criticism; fewer doctors are seeing reps; two Copaxone patents are invalidated

Analysts: Payers moving to address MS market as prices rise

Analysts: Payers moving to address MS market as prices rise

By

The impending payer crackdown of the cost of MS drugs could portend the fate of other specialty drug markets, according to analysts.

Biogen turned to DTC to address 'low awareness' of MS drug

Biogen turned to DTC to address 'low awareness' of MS drug

By

Biogen CEO George Scangos told investors that the company's DTC campaign for Tecfidera was designed to address low awareness for the drug.

Biogen slashes workforce, invests in Tecfidera DTC

Biogen slashes workforce, invests in Tecfidera DTC

By

The company plans to run the campaign through 2016 to counteract slowing sales for Tecfidera.

Five things for pharma marketers to know: Wednesday, August 5

Five things for pharma marketers to know: Wednesday, August 5

By

The FDA updates Gilenya's label over definite case of PML; generic drug companies are consolidating for negotiating power; the FDA revises guidance on DTC risk information

Five things for pharma marketers to know: Friday, July 24

Five things for pharma marketers to know: Friday, July 24

By

UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth

Novartis exec: Pharma culture can be stumbling block to creativity

Novartis exec: Pharma culture can be stumbling block to creativity

By

It's not always regulation or concerns about legal risks. Sometimes, a drugmaker's internal conservative culture is the biggest hurdle to overcome.

Five things for pharma marketers to know: Tuesday, May 26

Five things for pharma marketers to know: Tuesday, May 26

By

Experimental psoriasis drug linked to suicidal thoughts; analysis finds that some high prescribers receive non-research industry money; researchers say new MS drugs spur higher prices of older medications

Five things for pharma marketers to know: Monday, April 27

Five things for pharma marketers to know: Monday, April 27

By

More pharma companies hike drug prices post-acquisition; HCV linked to increased risk of cancer; a combined Teva-Mylan would control 25% of the US generic drug market

Biogen, PatientsLikeMe use Fitbit to better understand MS

Biogen, PatientsLikeMe use Fitbit to better understand MS

By

The drugmaker and patient network teamed up to establish a formal framework for deploying activity trackers for patients with MS and for capturing that data.

Five things for pharma marketers to know: Monday, April 13

Five things for pharma marketers to know: Monday, April 13

By

Sanofi won't discount new insulin; Takeda appoints new US business head; insurers push back on expensive preventative genetic tests

Five things for pharma marketers to know: Wednesday, February 18

Five things for pharma marketers to know: Wednesday, February 18

By

Researchers find repeat marketing offenders in the UK and Sweden, Actavis plans to take Allergan's name and Sanofi enters an auto-immune disease collaboration.

Biogen adds football, basketball talent for MS campaign

Biogen adds football, basketball talent for MS campaign

By

MS drugmaker Biogen Idec drafted Tyler Campbell, son of NFL Hall of Fame running back Earl Campbell, and former Dallas Mavericks point guard Chris Wright to help inspire sufferers of multiple sclerosis.

Supreme Court says Teva MS patent stands (for now)

The ruling stalls generics until at least September.

Patients to influence voice of Lemtrada consumer campaign

Patients to influence voice of Lemtrada consumer campaign

By

Patient advocates lobbied the FDA to approve the MS drug and Sanofi subsidiary Genzyme says their voice will be part of the consumer outreach when DTC rolls out next year.

Gilenya fails to help primary progressive MS patients

Novartis released Phase-III study results Monday.

AbbVie, Biogen to file MS drug next year

AbbVie, Biogen to file MS drug next year

By

Phase-III results of the AbbVie-Biogen Idec experimental multiple sclerosis shot Zinbryta (daclizumab) indicate the drug bests Avonex (interferon beta-1a) on some measures among relapse-remitting MS patients.

Sanofi wants greater MS role

The plan is to bring in-house products to the market as well as through acquisitions.

Biogen twice-monthly MS drug approved

Biogen twice-monthly MS drug approved

By

Plegridy is the only pegylated beta-interferon drug approved for relapsing multiple sclerosis.

Court won't stall generic Copaxone

Court won't stall generic Copaxone

By

The Supreme Court denied Teva's request to keep branded Copaxone off the market while the appeals process shakes out.

NICE gives Aubagio the nod

The price watchdog said Sanofi's oral MS drug Aubagio is a go. The decision follows a September directive to prove the drug's cost-effectiveness.

Biogen CEO cautions on Tecfidera EU launch

Biogen CEO cautions on Tecfidera EU launch

By

The MS pill saw rapid uptake in the US last year, but its overseas launch won't be as quick, CEO George Scangos conceded this week at an analyst conference.

The year's most popular stories

The year's most popular stories

Our year-end list captures the 10 that sparked heaviest interest.

Lemtrada US rejection snarls Sanofi

Lemtrada US rejection snarls Sanofi

By

The firm has vowed to appeal an FDA rejection that otherwise complicates its bid to expand in multiple sclerosis.

Osbourne joins Teva for "You Don't Know Jack About MS"

Osbourne joins Teva for "You Don't Know Jack About MS"

By

Famous from his reality show, "The Osbournes," Jack narrates his life with MS in a web documentary series.

Teva unclear on 2014 future

The company released two financial scenarios. The key is generic Copaxone.

Panel's Lemtrada endorsement not a rallying call

Panel's Lemtrada endorsement not a rallying call

By

Reviewers supported the drug's approval, but concerns about REMS and clinical trial integrity indicate the vote was not a roaring endorsement.

Small patient majority supports risky Sanofi MS drug: poll

Small patient majority supports risky Sanofi MS drug: poll

By

Most patients would advise today's FDA Lemtrada panel to allow doctors to gauge the drug's risk-benefit profile, although there was strong sentiment on either side of the issue.

OPINION

Email Newsletters